Rodman & Renshaw Initiates Coverage on Cancer Genetics Inc(NASDAQ:CGIX). The shares have been rated Buy. The rating by Rodman & Renshaw was issued on Sep 26, 2016.
Cancer Genetics Inc (CGIX) shares turned negative on Thursdays trading session with the shares closing down -0.04 points or -2.15% at a volume of 49,851. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $1.8999. The peak price level was also seen at $1.8999 while the days lowest was $1.8. Finally the shares closed at $1.82. The 52-week high of the shares is $10.06 while the 52-week low is $1.72. According to the latest information available, the market cap of the company is $29 M.
Cancer Genetics Inc(CGIX) last announced its earnings results on Aug 9, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $7.00M. Analysts had an estimated revenue of $6.50M. Earnings per share were $-0.28. Analysts had estimated an EPS of $-0.33.
Several Insider Transactions has been reported to the SEC. On Aug 17, 2016, John Pappajohn (director 10% owner) purchased 45,000 shares at $2.29 per share price.Also, On Mar 18, 2016, Howard Mcleod (director) purchased 1,000 shares at $2.71 per share price.On Mar 17, 2016, Panna Sharma (CEO) purchased 1,500 shares at $2.59 per share price, according to the Form-4 filing with the securities and exchange commission.
Cancer Genetics Inc. is an oncology diagnostics company focused on developing commercializing and providing DNA-based tests and services. The business is based on demand for DNA-based diagnostic services from three main sectors including cancer centers and hospitals biotechnology and biopharmaceutical companies and the research community. Its clinical offerings include its portfolio of proprietary tests targeting hematological urogenital and HPV-associated cancers in conjunction with ancillary non-proprietary tests. Biopharma services include laboratory and testing services performed for biopharmaceutical companies engaged in clinical trials. Discovery services provide the tools and testing methods for companies and researchers seeking to identify new DNA-based biomarkers for disease.